Literature DB >> 28285612

Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy.

Marco Cascella1, Maria Rosaria Muzio2.   

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and severe adverse effects related to cancer treatment. Unfortunately, although several agents and protocols have been proposed, no prophylactic strategies have yet to be proven useful. Therefore, new alternative therapies have been considered for CIPN prevention. Herbal medicine in Japan, called Kampo medicine, is derived from traditional Chinese medicine. Goshajinkigan (GJG) is a Kampo medicine, that is comprised of ten herbs. The aim of this work is to analyse the results of pre-clinical and clinical studies on the potential applications of GJG in CIPN prevention.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28285612     DOI： 10.1016/S2095-4964(17)60313-3

Source DB:  PubMed          Journal:  J Integr Med


  16 in total

1.  Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.

Authors:  Nobuaki Hoshino; Riki Ganeko; Koya Hida; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2017-12-21       Impact factor: 3.402

2.  Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.

Authors:  Akira Kuriyama; Koji Endo
Journal:  Support Care Cancer       Date:  2017-12-26       Impact factor: 3.603

3.  Suppressive effects of processed aconite root on dexamethasone-induced muscle ring finger protein-1 expression and its active ingredients.

Authors:  Taishi Kondo; Tomoaki Ishida; Ke Ye; Marin Muraguchi; Yohei Tanimura; Masato Yoshida; Kan'ichiro Ishiuchi; Tomoki Abe; Takeshi Nikawa; Keisuke Hagihara; Hidetoshi Hayashi; Toshiaki Makino
Journal:  J Nat Med       Date:  2022-02-18       Impact factor: 2.343

Review 4.  The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre-clinical studies and translational perspectives in clinical practice.

Authors:  Marco Cascella; Sabrina Bimonte; Maria Rosaria Muzio; Vincenzo Schiavone; Arturo Cuomo
Journal:  Infect Agent Cancer       Date:  2017-06-19       Impact factor: 2.965

5.  Goshajinkigan, a Traditional Japanese Medicine, Suppresses Voltage-Gated Sodium Channel Nav1.4 Currents in C2C12 Cells.

Authors:  Ryota Imai; Shoichiro Horita; Yuko Ono; Keisuke Hagihara; Masaru Shimizu; Yuko Maejima; Kenju Shimomura
Journal:  Biores Open Access       Date:  2020-04-27

6.  Search of anti-allodynic compounds from Plantaginis Semen, a crude drug ingredient of Kampo formula "Goshajinkigan".

Authors:  Kazufumi Toume; Zhiyan Hou; Huanhuan Yu; Mitsuru Kato; Miki Maesaka; Yanjing Bai; Shiho Hanazawa; Yuewei Ge; Tsugunobu Andoh; Katsuko Komatsu
Journal:  J Nat Med       Date:  2019-06-12       Impact factor: 2.343

7.  Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yihong Liu; Brian H May; Anthony Lin Zhang; Xinfeng Guo; Chuanjian Lu; Charlie Changli Xue; Haibo Zhang
Journal:  Integr Cancer Ther       Date:  2018-12-10       Impact factor: 3.279

8.  Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System.

Authors:  Shiying Jiang; Kousuke Baba; Keisuke Hagihara; Hideki Mochizuki; Tatsusada Okuno; Makoto Kinoshita; Chi-Jing Choong; Hideki Hayakawa; Hiroshi Sakiyama; Kensuke Ikenaka; Seiichi Nagano; Tsutomu Sasaki; Munehisa Shimamura; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2020-10-20       Impact factor: 7.620

Review 9.  Kampo for the Treatment of Pain in Japan: A Review.

Authors:  Young-Chang Arai; Izumi Makino; Tatsunori Ikemoto; Hironori Saisu; Yuki Terajima; Keiko Owari
Journal:  Pain Ther       Date:  2020-03-10

10.  Mechanical allodynia triggered by cold exposure in mice with the Scn11a p.R222S mutation: a novel model of drug therapy for neuropathic pain related to NaV1.9.

Authors:  Yosuke Matsubara; Hiroko Okuda; Kouji H Harada; Shohab Youssefian; Akio Koizumi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-09-24       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.